In addition, Biognosys secured consulting support from Patrick Plewman, the former Chief Executive Officer of diaDexus. Patrick holds a BA degree from the University of North Carolina at Chapel Hill and was awarded an MBA from Harvard Business School. Last ten years Patrick served as the CEO of diaDexus where he led the company from concept to commercialization of the only FDA approved blood test to predict coronary heart disease and ischemic stroke. At diaDexus he raised over $100 million in multiple financing rounds. Previously while at SmithKline Beecham, he witnessed the transformation of pharmaceutical research powered by novel genomic technologies. “I believe novel proteomic technologies such as Biognosys’ Hyper Reaction Monitoring technology have similar transformative capabilities”, Patrick said.
“Patrick’s expertise in molecular diagnostics and raising capital is valuable to the continued success of Biognosys”, said Oliver Rinner, Managing Director & CSO of Biognosys.
We are looking forward to a promising 2013.